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OBJECTIVES The purpose of this work was to establish the normal range of maximal renal hyperemic
response in humans and to identify the ideal renal vasodilatory stimuli.
BACKGROUND Stenotic renovascular atherosclerosis is increasingly treated by percutaneous transluminal
renal intervention but with an unpredictable outcome. This may be due to hemodynamically
non-significant stenosis or the presence of irreversible damage to the glomerular circulation.
We propose that the renovascular hyperemic response may help identify appropriate patients.
METHODS In 28 normotensive patients, quantitative angiographic measurements of the renal artery were
obtained, and renal artery pressure and flow velocity were continuously recorded after various
hyperemic agents.
RESULTS In a first group of 11 patients, a significant increase in renal artery average peak velocity
(APV) was observed after intrarenal (IR) bolus injection of 600 g isosorbide dinitrate (41 
19%), 30 mg papaverine (50  34%), 50 g dopamine (94  54%), 0.8 g·kg1 fenoldopam
(80 25%), and during IR infusion of 1 g·kg1·min1 fenoldopam (86  28%). A second
group of 17 patients received intravenous infusion of dopamine (3, 5, 10, 20, 30, and 40
g·kg1·min1). The 3 and 5 g·kg1·min1 of dopamine modestly reduced renal
resistance index (RI) (13  15% and 25  20%, respectively). At higher dosages, no
further decline in RI was observed. No significant change in vessel diameter was observed
before and after the administration of the pharmacological stimuli suggesting that changes in
APV corresponded with changes in absolute renal blood flow.
CONCLUSIONS The normal renal flow reserve averages approximately 2 in humans with normal renal
function. An IR bolus injection of 50 g·kg1 of dopamine is the most convenient means to
elicit maximal renal hyperemia. (J Am Coll Cardiol 2006;47:620–5) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.08.071American College of Cardiology Foundation
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aenal artery stenosis (RAS) may lead to renal failure and
ifficult in controlling hypertension (1), with comorbidity
eaching approximately 10% to 20% in patients with docu-
ented coronary atherosclerosis (2,3). Despite percutaneous
enal intervention (PRI) being used increasingly to treat
AS (4–6), decline in renal function after PRI (1), sub-
tantial restenosis (7) rates, and the absence of clinical
enefit in 30% to 40% of patients have been reported (1).
his variable response to revascularization is likely to be due
o the presence of irreversible renal injury (8) and/or to the
election of patients with physiologically non-significant
enal stenoses. Better patient selection may, therefore,
mprove outcome.
From the *Cardiovascular Centre Aalst, OLV-Clinic, Aalst, Belgium; †Depart-
ent of Cardiology, Catharina Hospital Eindhoven, Eindhoven, the Netherlands;
Department of Nephrology, University of Ghent, Ghent, Belgium; and the
Department of Epidemiology, OLV-Clinic, Aalst, Belgium. Dr. Ganesh Manoha-
an is a recipient of the Berkeley Fellowship (awarded jointly by the Master and
ellows of Gonville and Caius College, Cambridge, and the Dean and Board of the
aculty of Clinical Sciences of Royal Free and University College Medical School of
CL, London, United Kingdom) and the Samuel Haslett Browne Scholarship
awarded by the Faculty of Medicine and Health Sciences, Queen’s University of
elfast, United Kingdom).l
Manuscript received June 22, 2005; revised manuscript received July 25, 2005,
ccepted August 8, 2005.At the level of the coronary circulation, maximal hyper-
mia is paramount in assessing the physiologic severity of
tenoses detected at angiography. By analogy, we propose
hat pressure or flow measurements performed under con-
itions of maximal renal hyperemia might be important to
etermine the true severity of the renal stenoses and, hence,
o identify the patients who will benefit from PRI.
The aim of the present study, therefore, was to establish
he range of normal maximal renal hyperemic response in
umans and to identify the ideal renal vasodilatory stimuli.
ETHODS
atient selection. A total of 28 patients (20 men, mean age
5 8 years, range 27 to 74 years) participated in the study.
ll patients were normotensive (systolic 100 mm Hg 
ge and diastolic90 mm Hg), had a normal renal function
creatinine clearance 100 mg/ml), and a normal glycemic
ontrol. They underwent cardiac catheterization for the
ollowing reasons: patent foramen ovale or mild atrium
eptum defect (n  6), mild mitral regurgitation or mild
ortic regurgitation (n  4), atypical chest pain (n  11),
imited (one-vessel) coronary artery disease (n 7). Cardiac
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February 7, 2006:620–5 Renal Flow Reserveedications were interrupted at least 24 h before the
atheterization. In a first group of 11 patients, various
harmacologic hyperemic stimuli (isosorbide dinitrate, pa-
averine, fenoldopam, dopamine) were given intrarenally
IR). In a second group of 17 patients, dopamine was
nfused intravenously (IV). The study was approved by the
nstitutional ethical review boards of the Onze-Lieve Vrouw
iekenhuis, Aalst, Belgium, and of the Catharina Hospital
indhoven, the Netherlands, and informed consent was
btained from all patients.
tudy protocol. After the introduction of a 6-F sheath into
he femoral artery, a 6-F right coronary guiding catheter was
ositioned at the ostium of the right or the left renal artery,
nd 400 g isosorbide dinitrate was given to avoid changes
Abbreviations and Acronyms
APV  average peak velocity
HR  heart rate
IR  intrarenal
IV  intravenous
MBP mean blood pressure
PRI  percutaneous transluminal renal intervention
RAS  renal artery stenosis
RI  renal vascular resistance index
igure 1. Example of simultaneous pressure and velocity pressure tracing
opamine (DOPA); immediately after administration of the bolus, a marked decr
wo-fold increase in flow velocities without changes in blood pressure nor in hen diameter of the main renal artery. A 0.014-inch Doppler
ow (FloWire, Volcano, Mountain View, California) wire
as introduced into the renal artery and positioned under
uoroscopy in order to obtain an optimal and stable flow
elocity signal. A high-quality renal angiogram was then
erformed allowing quantitative angiography (CAAS II,
ie Medical Imaging, Maastricht, the Netherlands). Mea-
urement of the diameter of the renal artery was performed
mm distal to the tip of the FloWire as this is the very place
here the velocity is measured by the FloWire. This allowed
s to calculate absolute renal blood flow and renal resistance.
he guide catheter was used as a scaling device. Baseline flow
elocity was measured and recorded for at least 2 min to ensure
steady-state baseline flow velocity. Next, the varying phar-
acological stimuli, as described in the following text, were
dministered with renal artery pressure and blood flow velocity
eing continuously recorded. All pressure and flow measure-
ents were stored digitally for analysis. At the end of the
rocedure, another renal angiogram was performed for quan-
itative analysis, and the catheters and sheaths were removed.
n example of baseline and hyperemic pressure and flow
elocity tracings is shown in Figure 1.
harmacological stimuli. IR ADMINISTRATION. Eleven
atients received successively the following medications at
e, during, and after intrarenal administration of a bolus of 50 g·kg1 ofbefor
ease in renal artery average peak velocity is observed, followed by an almost
art rate.
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Renal Flow Reserve February 7, 2006:620–5he following dosages: 1) IR bolus injection of 600 g
sosorbide dinitrate; 2) IR bolus injection of 30 mg papav-
rine; 3) IR incremental bolus injections of 10, 15, 20, 25,
nd 50 g/kg dopamine; 4) IR bolus of 0.05, 0.1, 0.2, 0.4,
nd 0.8 g/kg fenoldopam (each bolus injection was sepa-
ated by at least 2 min); 5) IR infusion of 0.1, 0.3, and
g/kg/min fenoldopam (each dosage was maintained
uring at least 2 min). The order of administration was
nchanged throughout the study.
V INFUSION OF DOPAMINE. Seventeen patients received an
V infusion of dopamine at incremental dosages of 3, 5, 10,
0, 30, and 40 g/kg/min. Dosages of 3 and 5 were
aintained during 5 min each; higher dosages were main-
ained during 2 min each.
We waited for the average peak velocity (APV) to return
o baseline for nitrates and papaverine before administration
f other vasodilators. For the longer-acting agents, we
lways waited at least 5 min between two different vasodi-
ators, and, for the same vasodilator, we always waited for a
teady state of at least 2 min. When it was clear that a given
osage would not elicit a higher vasodilator response, the
ext dosage was administered.
ata analysis. Renal flow reserve was defined as renal
rtery APV during pharmacological stimulation divided
y renal artery APV at baseline. Changes in renal artery
PV are expressed as percent increase as compared to
aseline. Renal vascular resistance index (RI) (dimen-
ionless) was calculated as the ratio of mean blood
ressure (MBP) to APV.
tatistics. Data are expressed as mean  SD. Gaussian
istributions of data were tested by Kolmogorov-Smirnov
est. A repeated measures analysis of variance was used to
tudy the effects of the different drug doses on the following
ariables: APV, MBP, heart rate (HR), and RI. Post-hoc
omparisons between treatment groups were performed
sing the Bonferroni adjustment for multiple comparisons.
able 1. Renal Artery APV, MBP, HR, and RI at Baseline and
APV,
cm·s1
aseline 33  5
sosorbide dinitrate IR (bolus) 600 g 49  14*
apaverine IR (bolus) 30 mg 50  16*
opamine IR (bolus) 5 g·kg1 52  16*
opamine IR (bolus) 10 g·kg1 54  15*
opamine IR (bolus) 15 g·kg1 57  26*
opamine IR (bolus) 20 g·kg1 61  18*
opamine IR (bolus) 30 g·kg1 62  22*
opamine IR (bolus) 50 g·kg1 65  20*
enoldopam IR (bolus) 0.05 g·kg1 53  15*
enoldopam IR (bolus) 0.1 g·kg1 56  13*
enoldopam IR (bolus) 0.2 g·kg1 57  14*
enoldopam IR (bolus) 0.4 g·kg1 58  13*
enoldopam IR (bolus) 0.8 g·kg1 60  13*
enoldopam IR (infusion) 0.1 g·min1·kg1 55  13*
enoldopam IR (infusion) 0.3 g·min1·kg1 63  15*
enoldopam IR (infusion) 1 g·min1·kg1 62  15*p  0.05 vs. baseline. p values were Bonferroni-adjusted (17 treatment groups [including
APV  average peak velocity; HR  heart rate; IR  intrarenally; MBP  mean bloopaired t test was used to compare the dimensions of the
enal artery before and at the end of the study protocol. An
npaired t test or the Mann-Whitney U test (if the
istribution is not normal) was used to compare APV and
I values obtained after renal and after IV administration of
opamine. For all analysis, a p value of 0.05 was consid-
red non-significant. All analyses were performed using the
oftware package SPSS 11.5 (SPSS Inc., Chicago, Illinois).
ESULTS
imensions of the renal artery. There were no significant
hanges in the diameter of the renal artery before and at the
nd of the administration of the renal vasodilators (5.51 0.90
m before vs. 5.49 0.90 mm after, pNS). Therefore, the
hanges in renal artery average peak blood flow velocity can be
onsidered proportional to volumetric renal blood flow.
ffect of IR vasodilators. The values of renal artery
PV, MBP, HR, and RI at baseline and after each of the
R vasodilators tested are given in Table 1. Figure 2
isplays the percent changes in APV and RI induced by
he various IR vasodilators tested. All hyperemic stimuli
ssessed in this study resulted in a significant increase in
enal blood flow with respect to baseline measurements
F(5.36, 53.64)  14.20, p  0.001, 2  0.59).
ntrarenal bolus administration slightly increased HR
F(3.93, 39.36)  3.32, p  0.020, 2  0.25) and
ecreased blood pressure (F(2.91, 29.07)  5.36, p 
.001, 2  0.36). Accordingly, the increase in APV was
aralleled by a significant decrease in RI (F(4.84, 48.36) 
8.02, p  0.001, 2  0.64). The largest increase in APV
as observed for dopamine delivered as an IR bolus of 50
g·kg1 (94 55%, range 40% to 214%). In all patients, all
R bolus administrations of dopamine were followed by a
iphasic flow response: maximal hyperemia was preceded by
short-lasting decrease in renal blood flow (Fig. 1). The
ng the Peak Effect of the Vasodilatory Stimuli as Given IR
MBP,
mm Hg
HR,
beats/min
RI,
cm·s1·mm Hg1
101  16 67  10 3.10  0.67
100  15 70  12 2.14  0.61*
85  20* 77  12* 1.88  0.72*
88  19* 76  14 1.88  0.72*
86  13* 72  10 1.67  0.51*
85  18* 70  11 1.85  1.17*
88  13* 75  10 1.57  0.55*
89  14* 76  18 1.62  0.70*
86  11* 77  17 1.44  0.49*
93  17 70  11 1.94  0.83*
90  15 72  12 1.75  0.71*
91  14 71  11 1.74  0.71*
89  16* 73  12 1.59  0.40*
85  15 73  11 1.47  0.35
88  16* 72  10 1.80  0.63*
87  14* 74  9 1.45  0.34*
84  14* 77  10 1.39  0.29*Duribaseline]—136 possible comparisons). RI  MBP:APV.
d pressure; RI  renal resistance index.
m
w
i
E
M
d
c
d
d
(
(
(
(
F
i
m
p
F
p
r
d
623JACC Vol. 47, No. 3, 2006 Manoharan et al.
February 7, 2006:620–5 Renal Flow Reserveagnitude and duration of this transient decrease in flow
as dose-dependent. Dopamine and fenoldopam were sim-
lar in regard to the maximal effect on renal artery APV.
ffect of IV dopamine. The values of renal artery APV,
BP, HR, and RI at baseline and after each dosage of IV
opamine are given in Table 2. Figure 3 displays the percent
hanges in APV, MBP, and RI induced by the different
osages of IV dopamine. The main effect of increasing the
igure 2. Percent increase in renal artery average peak velocity (APV) after
ntrarenal administration of various vasodilatory stimuli. Dopa  dopa-
ine; Fenol  fenoldopam; ISDN  isosorbide dinitrate; PAPAV 
apaverine; RI  renal vascular resistance index.
Table 2. Renal Artery APV, MBP, HR, and R
a Continuous IV of Dopamine
APV,
cm·s1
Baseline 33  11
Dopamine IV 3 g·kg1·min1 37  3*
Dopamine IV 5 g·kg1·min1 44  15*†
Dopamine IV 10 g·kg1·min1 46  16*
Dopamine IV 20 g·kg1·min1 48  14*
Dopamine IV 30 g·kg1·min1 50  17*
Dopamine IV 40 g·kg1·min1 49  10*
*p  0.05 vs. baseline; †p  0.05 vs. previous value. p
baseline]—21 possible comparisons). RI  MBP:APV.
Abbreviations as in Table 1.osage of dopamine IV was statistically significant on APV
F(3.18, 50.91)  14.08, p  0.001, 2  0.47), RI
F(3.00, 48.15)  4.14, p  0.011, 2  0.21), HR
F(3.34,53.43)  25.21, p  0.001, 2  0.61), and MBP
F(2.46,39.35)  12.038, p  0.001, 2  0.44).
Baseline and at the End of Each Dosage of
BP,
m Hg
HR,
beats/min
RI,
cm·s1·mm Hg1
7  16 64  12 3.25  1.36
6  15 65  11 2.99  1.52*
5  15 66  11 2.56  1.41*†
2  15 67  11 2.59  1.24*
3  20* 74  13* 2.63  1.02*
7  17* 88  18* 2.62  1.07*
1  17* 94  17* 2.60  0.70*
were Bonferroni-adjusted (7 treatment groups [including
igure 3. Percentage change in renal artery average peak velocity (upper
anel), in mean arterial blood pressure (mid-panel), and in renovascular
esistance index (lower panel) during the intravenous infusion of increasing
osages of dopamine. BL  baseline.I at
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Renal Flow Reserve February 7, 2006:620–5Dosages of 3 and 5 g·kg1·min1 (“renal dosages”)
nduced a weak, albeit significant, increase in APV (17 
9% and 39  8%, respectively, both p  0.05 as compared
o baseline values). The corresponding values of decrease in
I renal resistance index were13 15% and25 20%,
espectively (p 0.01 as compared to baseline values). From
0 to 40 g·kg1·min1, a more pronounced increase in
PV occurred. These higher dosages of dopamine were
aralleled by an increase in blood pressure but no further
ecrease in RI. The largest increase in APV obtained with
V dopamine (66  59%) was smaller than with IR
opamine (94  55%, p  0.023 [unpaired t test]). The
aximal decrease in renal RI that was observed with 5 g
g1·min1 (25  20%) of IV dopamine remained
ignificantly smaller than the largest decrease obtained with
R dopamine (52  14%, p  0.001 [unpaired t test]).
ISCUSSION
he present study provides, for the first time, a direct
ocumentation of the renovascular response to various
yperemic agents in man by continuous and simultaneous
ssessment of flow velocity and pressure in the renal artery.
he data indicate that, in patients with normal renal
unction and angiographically normal renal arteries, renal
ow reserve averages approximately 2, varying from 1.4 to
.1. The most potent, easiest, and cheapest means for achiev-
ng maximal renal hyperemia is an IR bolus of dopamine of 30
o 50 g·kg1. Although we did not investigate the effect of
igher bolus doses, no significant difference was observed
etween the 30 and 50 g·kg1 suggesting a plateau has
een reached. It is proposed that the renal hyperemic
esponse might be useful in identifying hemodynamically
ignificant RAS. Furthermore, the actual induction of a
yperemic response by the kidney suggests persistence of renal
asoreactivity, which may aid in identifying viable renal paren-
hyma and help in selecting patients in whom revascularization
f a RAS leads to a favorable outcome. In addition, the study
onfirms that “renal dosages” of 3 to 5 g·kg1·min1 of
opamine administered IV induce a significant increase in
enal flow and decrease in renovascular resistance. Yet, at
igher dosages of IV dopamine, a further increase in renal flow
ppears mainly driven by an increase in systemic blood
ressure.
ethodologic considerations. Because the diameter of
he renal artery was similar at baseline and at the end of the
tudy, renal artery APV could be considered proportional to
hanges in volumetric blood flow. However, no attempt was
ade to calculate volumetric renal blood flow on the basis of
he dimensions of the vessel, the APV, and HR. The exact
ampling place along the diameter of the vessel as well as the
ncertainty about the shape of the parabolic profile of renal
lood flow at the place of sampling introduce many approx-
mations that might lead to large and uncontrolled inaccu-
acies (9). Therefore, it was considered reasonable to limit
he evaluation of the renovascular hemodynamics to flow aelocities and renovascular resistance index instead of volu-
etric flow and absolute renovascular resistance.
enal hyperemia. The results observed in the present study
re in line with earlier animal experiments. In anesthetized
ogs, a biphasic renal flow response after IR infusion of
opamine was observed: a dose-dependent short-lasting
ecrease in flow was followed by an increase of approxi-
ately 30% of renal blood flow for a bolus of approximately
0 g·kg1 (10). Swain et al. (11) showed that in conscious
ogs and baboons that a 45-s occlusion of the renal artery
as followed by a “flow repayment” of 85  9% (corre-
ponding to a renal flow reserve of 1.85), which is remark-
bly similar to what we found in humans after an IR bolus
f 50 g·kg1 of dopamine. In animals, this hyperemic
esponse was almost abolished by IV indomethacine, an
nhibitor of prostaglandin synthesis.
Mounier-Vehier et al. (12) recently suggested that
apaverine-induced increase in renal blood flow could be
seful in evaluating the repercussions of a renal stenosis on
he distal vasculature. Similar to our findings, these authors
eported a vasodilator reserve of 1.6 in non-stenotic renal
rteries after administration of 40 mg papaverine. A similar
nding was observed by Beregi et al. (13), with vasodilator
eserve of 1.5, after administration of 40 mg of papaverine in
ypertensive patients with normal renal arteries. Yet the
resent data suggest that both dopamine and fenoldopam
nduce a more potent decrease in renovascular resistance
nd, consequently, a larger increase in renal flow.
We did not study the effects of adenosine, which is used
o induce hyperemia in coronary circulation, as it induces a
otent vasoconstrictor effect on the renal circulation.
opamine versus fenoldopam. Dopamine is an endoge-
ous catecholamine of which the renal effects are mediated
y the dopaminergic DA1 and, to a lesser extent, DA2
eceptors and adrenergic alpha-1, alpha-2, and beta-1 recep-
ors. These respective effects are dose-dependent. DA1
eceptors have a vasodilatory action on the main renal artery,
he afferent and the efferent arteriole. Fenoldopam is a
lightly more potent agonist on DA1 receptors but does not
ct as an agonist on DA2 receptors or alpha- and beta-
drenergic receptors (14). The present data did not show
ny significant difference between dopamine and fenoldo-
am given as IR boluses. Therefore, it is suggested that
opamine is the ideal renal vasodilator because, in addition
o producing maximal hyperemia, it is cheaper and more
idely available than fenoldopam.
linical implications. Fortuitous diagnosis of RAS has
ecome common (15), resulting in the growth of PRI being
erformed but with only a minority of patients actually
enefiting from the procedure (1). The reasons for poor
utcome after renal angioplasty observed in studies could be
ue to inclusion of patients with angiographically “signifi-
ant” but hemodynamically non-significant stenosis and
erforming renal angioplasty on kidneys with significant
arenchymal tissue damage. At present, there is no test to
ccurately select patients who will benefit from renal angio-
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February 7, 2006:620–5 Renal Flow Reservelasty. The decision to perform an angioplasty is most often
riggered by an angiographic image, whereas the relationship
etween the angiographic appearance and hemodynamic im-
act of the stenosis is very poor (16). It is suggested that the
enal artery pressure gradient as measured with 0.014-inch
ressure-monitoring guide wires, rather than thin catheters,
ould be better at selecting those patients who are likely to
enefit from an angioplasty (17). In addition, and by
nalogy with what happens in the coronary circulation, it is
ossible that the hyperemic pressure gradient (rather than
he mere resting gradient) or the ratio of hyperemic distal-
o-proximal renal pressure (“renal fractional flow reserve”)
ay provide more useful information on the extent to which
he renal blood flow is limited by the presence of the
tenosis. However, in order to accurately measure and
uantify renal fractional flow reserve, an ideal hyperemic
gent is required, and, as was observed in this study, IR
olus of dopamine at 30 to 50 g·kg1 appears to be an
fficient method.
In contrast to the coronary circulation, a significant
ransstenotic pressure gradient indicating a hemodynami-
ally important RAS can be masked by constriction of the
fferent artery. Therefore, an appropriate hyperemic stimu-
us to unmask significant stenosis should have a vasodilatory
ffects on both the afferent and the efferent artery. Unlike
denosine, dopamine appears to be such a stimulus. Further
tudies are mandatory to establish what magnitude of
hyperemic) gradient or which value of “renal fractional flow
eserve” indicates a significant stenosis (i.e., a stenosis
eading to renovascular hypertension and ischemic nephrop-
thy). It is speculated that a resting renal artery pressure
radient that increases after IR bolus injection of dopamine
ndicates that there is both a hemodynamically significant
tenosis and a well-functioning parenchymatous blood flow
egulation.
Goldberg et al. (18) first introduced the concept of protec-
ive effect of low-dose dopamine. It is generally accepted that
nfusion rates smaller than 5 g·kg1·min1 produce stimula-
ion of dopaminergic receptors with an increase in renal blood
ow and of glomerular filtration rate without accompanying
ncrease in blood pressure and HR. The present study
onfirms a decrease in renovascular resistance by 25% with
g·kg1·min1. From 5 to 10 g·kg1·min1,
-adrenergic effects predominate and -adrenergic effects
radually become important. Infusion rates larger than 10
g·kg1·min1 produce mainly - and -adrenergic effects
ith a trend toward vasoconstriction. An increase in renal
rtery APV of 17% and 39% with infusion rates of 3 and 5
g·kg1·min1, respectively, supports the earlier findings of
oldberg et al. (18). Whether this effect is maintained in
atients with renal dysfunction and comorbidities is de-
ated, with some current evidence suggesting that low-dose
opamine is ineffective in critically ill patients (19,20).
This study could be summarized as follows: 1) renal floweserve is approximately 2, and dopamine IR (50 g·kg1 as
2bolus) is the easiest means to achieve maximal renal
yperemia; the latter could be useful in identifying the
emodynamic severity of renal stenosis; 2) low-dose IV
opamine induces a limited, albeit significant, increase in
enal blood flow in normals. The present data provide a
eference for normal renal artery flow reserve and a basis for
ssessing the renovascular status in diseased states such as
ypertension, diabetes mellitus, and RAS.
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